/PRNewswire/ OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies
June 30, 2021 GMT
NEW YORK, June 29, 2021 /PRNewswire/ OnCusp Therapeutics (or “OnCusp”), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative oncology therapeutics, announced that it has officially commenced operations both in New York and Shanghai.
OnCusp successfully closed its seed round founding of $25 million on April 1, 2021, led by Sequoia Capital and Biotrack Capital, followed by Oriza Seed Fund and AIHC Capital. Proceeds from this round will be used to build a portfolio of innovative assets, advance research and development programs, as well as support the company’s day-to-day operations and talent acquisition.